Welcome back to our weekly update on all things PREreview.org!
What’s new at PREreview?
As we continue developing our Structured PREreview workflow (which will take the place of our old Rapid PREReview workflow), we’re excited for all the new PREreviews being published by ASAPbio Crowds and their PREreview Clubs! Check them out!
- PREreview of “ATP10A promotes endothelial cell insulin sensitivity and protects against diet-induced dyslipidemia in female mice” by the ASAPbio Metabolism Crowd
- PREreview of “Exploring G-quadruplex structure in PRCC-TFE3 fusion Oncogene: Plausible use as anti cancer therapy for translocation Renal cell carcinoma (tRCC)” by the ASAPbio Cancer Biology Crowd
- PREreview of “Predicting causal citations without full text” by the ASAPbio Meta-Research Crowd
- PREreview of "Population encoding of stimulus features along the visual hierarchy” by the ASAPbio Neurobiology Crowd
- PREreview of “ATP10A promotes endothelial cell insulin sensitivity and protects against diet-induced dyslipidemia in female mice” by the ASAPbio Metabolism Crowd
- PREreview of “Amyloid β Induces Lipid Droplet-Mediated Microglial Dysfunction in Alzheimer’s Disease” by the ASAPbio Neurobiology Crowd
Keep up with our blog for more news on Clubs - and how to start your own - very soon!
What’s next?
Up next, we’ll be working on testing and releasing our Structured PREreview workflow, as well as updated profile pages, and new request-a-review integrations powered by the COAR Notify Protocol.
Let us know what you think
Share your PREreview experiences with PREreview.org anytime by scheduling a user research interview with Product Manager Chad Sansing. You can click here to sign up for a chat. If you can’t find a time that works for you, please email Chad to arrange a call. Whenever possible, we compensate interviewees.
You can join our community Slack and share your PREreview stories on the #community-feedback channel, as well.
Stay connected
Join us again next Friday for more news from PREreview.org.
Until then, you can find us on Mastodon, Twitter, and LinkedIn. Please also take a moment to subscribe to our newsletter.
